Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · IEX Real-Time Price · USD
2.675
-0.045 (-1.65%)
Jul 22, 2024, 10:15 AM EDT - Market open
Werewolf Therapeutics Employees
Werewolf Therapeutics had 47 employees as of December 31, 2023. The number of employees increased by 1 or 2.17% compared to the previous year.
Employees
47
Change (1Y)
1
Growth (1Y)
2.17%
Revenue / Employee
$345,128
Profits / Employee
-$884,660
Market Cap
117.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 47 | 1 | 2.17% |
Dec 31, 2022 | 46 | 7 | 17.95% |
Dec 31, 2021 | 39 | 15 | 62.50% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
American Well | 1,104 |
FONAR | 561 |
Agenus | 389 |
Akoya Biosciences | 330 |
Seer, Inc. | 147 |
KORU Medical Systems | 82 |
Athira Pharma | 67 |
Relmada Therapeutics | 20 |
HOWL News
- 27 days ago - Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewsWire
- 7 weeks ago - Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - GlobeNewsWire
- 7 weeks ago - Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting - GlobeNewsWire